An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy

PURPOSE: This open-label feasibility study assessed the tolerability of nintedanib 200 mg in combination with docetaxel 75 mg/m(2) as a starting dose in Japanese patients with a body surface area (BSA) < 1.5 m(2) and locally advanced or metastatic lung adenocarcinoma. METHODS: Eligible patients r...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Noboru, Kenmotsu, Hirotsugu, Goto, Koichi, Takeda, Koji, Kato, Terufumi, Takeda, Masayuki, Horinouchi, Hidehito, Saito, Isao, Sarashina, Akiko, Tanaka, Tetsuya, Morsli, Nassim, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132853/
https://www.ncbi.nlm.nih.gov/pubmed/30073583
http://dx.doi.org/10.1007/s00280-018-3649-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132853/
https://www.ncbi.nlm.nih.gov/pubmed/30073583
http://dx.doi.org/10.1007/s00280-018-3649-x

Ejemplares similares